Correlation Of TIGIT Expression Levels On CD4+ T Cells With Disease Severity In Psoriasis

Synopsis T‐cell immunoglobulin and ITIM domain (TIGIT), a co‐inhibitory receptor, suppresses CD4+ T‐cell responses by triggering CD155. The present study aims to investigate TIGIT expression and its effects on CD4+ T‐cell function in psoriasis. This week’s “MED FACT” discusses a clinical trial from Clinical and Experimental Dermatology, “TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis”. Authors: F. F. Wang, Y. Wang, L. Wang, T.

S. Wang, Y. P. Bai Key Takeaways Downregulation of TIGIT on CD4+ T cells may contribute to the pathogenesis of psoriasis. Objective: The objective of this study was to investigate TIGIT expression and its effects on CD4+ T‐cell function in psoriasis. Study Type: Controlled study Participants: 28 What Was The Need For This Study? T‐cell immunoglobulin and ITIM domain (TIGIT), a co‐inhibitory receptor,…